Findings

What do systematic reviews say?

11 questions · 11 findings · 8 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 45.5%GRADE not reported 2 · 18.2%Very low 0 · 0%Low 4 · 36.4%Moderate 0 · 0%High 0 · 0%

Anti‐CD20 mAb maintenance therapy vs observation

Health‐related quality of life · people with chronic lymphocytic leukaemia

1 finding from 1 review

Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 480 participants
Low

MSCs vs placebo or control

Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

The review found no eligible studies for this question.

1 finding from 1 review

Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombopoietin mimetics vs placebo

Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia

The review found no eligible studies for this question.

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bortezomib vs no bortezomib

Health‐related quality of life · All patients with a diagnosis of multiple myeloma

1 finding from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 717 participants
GRADE not reported

Yoga in addition to standard care vs standard‐of‐care therapy

Health‐related quality of life · participants with haematological malignancies

The review found no eligible studies for this question.

1 finding from 1 review

Yoga in addition to standard care for patients with haematological malignancies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

Health‐related quality of life · patients with acquired SAA

1 finding from 1 review

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Anti‐CD52 mAb maintenance therapy vs observation

Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia

The review found no eligible studies for this question.

1 finding from 1 review

Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Immunomodulatory drug maintenance therapy vs placebo/observation

Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia

The review found no eligible studies for this question.

1 finding from 1 review

Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ruxolitinib vs placebo

Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
RR 8.82 [4.4, 17.69]
1 study · 309 participants
Low

Ruxolitinib vs best available therapy

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · Patients with treating MF

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low

Eculizumab vs placebo

1 finding from 1 review

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low